Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
Frequently asked questions
What sector does Kadimastem Ltd (KMSTF) operate in?
Kadimastem Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kadimastem Ltd (KMSTF) current stock price?
As of the latest data, Kadimastem Ltd stock price is $2.47, with a previous close of $2.47.
What is Kadimastem Ltd (KMSTF) current market capitalization?
Kadimastem Ltd market cap is approximately 7.31 million.
What is Kadimastem Ltd (KMSTF) Earnings Per Share (EPS)?
The trailing EPS is -$6.35.
Does Kadimastem Ltd (KMSTF) pay dividends?
No. Kadimastem Ltd does not pay a dividend.
What is Kadimastem Ltd (KMSTF) beta (volatility) score?
Kadimastem Ltd has a beta of 0.574, indicating lower volatility than the overall market.